<SEC-DOCUMENT>0001157523-23-000021.txt : 20230106
<SEC-HEADER>0001157523-23-000021.hdr.sgml : 20230106
<ACCEPTANCE-DATETIME>20230106083021
ACCESSION NUMBER:		0001157523-23-000021
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20230106
FILED AS OF DATE:		20230106
DATE AS OF CHANGE:		20230106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FSD Pharma Inc.
		CENTRAL INDEX KEY:			0001771885
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39152
		FILM NUMBER:		23513801

	BUSINESS ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
		BUSINESS PHONE:		(416) 854-8884

	MAIL ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a53177141.htm
<DESCRIPTION>FSD PHARMA INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <div>
      <div style="text-align: center; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    </div>
    <div style="text-align: center; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 14pt;">
      <div style="text-align: center; color: rgb(35, 31, 32); font-weight: bold;">Form 6-K</div>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
    <div style="text-align: center; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16</div>
    <div style="text-align: center; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;">For the month of: <font style="font-weight: bold;"><u>January 2023</u></font></div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;">Commission File Number: <font style="font-weight: bold;"><u>001-39152</u></font></div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FSD PHARMA INC.</div>
      <div style="font-family: 'Times New Roman',Times,serif;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
    <div style="text-align: center; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;">(Translation of registrant&#8217;s name into English)</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">199 Bay St., Suite 4000</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Toronto, Ontario M5L 1A9, Canada</div>
    <div style="font-family: 'Times New Roman',Times,serif;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;">(Address of principal executive office)</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div><font style="font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32);">Form 20-F&#160;&#9746;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="color: rgb(35, 31, 32);">Form 40-F </font>&#9744;</font></div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: bold;">SIGNATURES</div>
    <div style="text-indent: 36pt; margin-top: 3pt; margin-bottom: 3pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
      be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div style="text-indent: 36pt; margin-top: 3pt; margin-bottom: 3pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="margin-top: 3pt; margin-bottom: 3pt; font-family: 'Times New Roman',Times,serif;">
      <table cellspacing="0" cellpadding="0" border="0" id="z7d506bdf70b444b2b6e092f21a2cfb63" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1" style="width: 3%;">
              <div>FSD Pharma Inc. <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1" style="width: 3%;">(Registrant)</td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; padding-bottom: 2px;">
              <div><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);">Date:&#160; January 6, 2023</font><font style="display: inline-block; text-indent: 0px; width: 216pt; font-family: 'Times New Roman',Times,serif;">&#160;</font> <br>
              </div>
            </td>
            <td style="width: 3%; padding-bottom: 2px;">
              <div><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);"><font style="color: rgb(0, 0, 0);">By:</font></font> <br>
              </div>
            </td>
            <td style="width: 47%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);"><font style="color: rgb(0, 0, 0);">/s/ Nathan Coyle</font></font> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%;">
              <div>Nathan Coyle, Chief Financial Officer <br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <br>
    <div style="text-align: center; margin-top: 3pt; margin-bottom: 3pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">EXHIBIT INDEX</div>
    <div style="margin-top: 3pt; margin-bottom: 3pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z60db33d8eee24d4e842e0988056b273f">

        <tr>
          <td style="width: 8%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>Exhibit</u></div>
          </td>
          <td style="width: 92%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>Description</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>
          <td style="width: 92%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0);">&#160;</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 8%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;"><a href="a53177141_ex991.htm">99.1</a> <br>
          </td>
          <td rowspan="1" style="width: 92%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;"><a href="a53177141_ex991.htm">Press Release &#8211; Dated January 6,
              2023 - FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023</a> <br>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a53177141_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div><font style="font-weight: bold;"> </font>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023</b> </h1>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>TORONTO--(BUSINESS WIRE)--January 6, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (&#8220;<b>FSD Pharma</b>&#8221; or the &#8220;<b>Company</b>&#8221;), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech
            solutions to address ailments affecting millions worldwide, announced today that senior executive management is attending the 41st Annual J.P. Morgan Healthcare Conference being held January 9-12, 2023, in San Francisco, California. The J.P.
            Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, connecting global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment
            community. </p>
          <p> Dr. Lakshmi P. Kotra, Director at FSD Pharma and Chief Executive Officer of the Company&#8217;s wholly owned subsidiary Lucid Psycheceuticals, and Zeeshan Saeed, Founder and President of FSD Pharma, will be in attendance and available for in-person
            meetings throughout the conference. </p>
          <p> <b>About FSD Pharma</b> </p>
          <p> FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, a
            proprietary ultra-micronized PEA formulation, for the treatment of inflammatory diseases. Lucid Psycheceuticals Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-Psych and Lucid-MS.
            Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>Forward Looking Information</b> </p>
          <p> Certain statements contained herein are &#8220;forward-looking statements.&#8221; Often, but not always, forward-looking statement can be identified by the use of words such as &#8220;plans&#8221;, &#8220;expects&#8221;, &#8220;expected&#8221;, &#8220;scheduled&#8221;, &#8220;estimates&#8221;, &#8220;intends&#8221;,
            &#8220;anticipates&#8221;, &#8220;hopes&#8221;, &#8220;planned&#8221; or &#8220;believes&#8221;, or variations of such words and phrases, or states that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221;, &#8220;potentially&#8221; or &#8220;will&#8221; be taken, occur or be achieved.
            Forward-looking statements contained in this press release include statements relating to the future of FSD Pharma Inc. FSD Pharma cannot give any assurance that such forward-looking statements will prove to have been correct. The reader is
            cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. </p>
          <p> Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions
            are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Factors that may cause such material
            differences include without limitation: the fact that the drug development efforts of both Lucid and FSD BioSciences are at a very early stage; the fact that preclinical drug development is uncertain, and the drug product candidates of Lucid
            and FSD BioSciences may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing
            of product development activities, preclinical studies and clinical trials of Lucid and FSD BioSciences; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive
            results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of Lucid and FSD BioSciences; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise
            superior to, the drug product candidates of Lucid and FSD BioSciences; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected, or impacted by COVID-19 related issues; the potential
            inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of Lucid and FSD BioSciences; and other risks. Further information regarding factors that may
            cause actual results to differ materially are included in the Company&#8217;s annual and other reports filed from time to time with the Canadian Securities Administrators on SEDAR (www.sedar.com) and with the U.S. Securities and Exchange Commission
            on EDGAR (www.sec.gov) under the heading &#8220;Risk Factors.&#8221; Any forward-looking statement contained in this release speaks only as of its date. The Company does not undertake to update any forward-looking statements, except to the extent required
            by applicable securities laws. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> Zeeshan Saeed, Founder, President and Executive Co-Chairman of the Board, FSD Pharma Inc. <br>
            Email: Zsaeed@fsdpharma.com<br>
            Telephone: (416) 854-8884 </p>
          <p> Investor Relations: <br>
            Email: ir@fsdpharma.com, info@fsdpharma.com<br>
            Website: www.fsdpharma.com </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
